Related Experiment Video
Updated: Dec 9, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.2K
More Focus is Needed to Reduce Adverse Events for Diabetes Devices.
1Krouwer Consulting, Sherborn, MA, USA.
Journal of Diabetes Science and Technology
|September 9, 2020
Summary
Adverse events in diabetes devices doubled from 2018 to 2019. Difficult FDA website tools and user error hinder efforts to address this growing safety concern for diabetes patients.
Area of Science:
- Medical device safety
- Diabetes technology
- Patient adverse events
Background:
- Diabetes device advancements have led to improvements in patient care.
- However, a significant increase in reported adverse events has been observed.
- The complexity of identifying and analyzing these events presents a considerable challenge.
Purpose of the Study:
- To highlight the escalating issue of adverse events associated with diabetes devices.
- To draw attention to the difficulties in accessing and interpreting FDA adverse event data.
- To encourage a greater focus on mitigating these safety concerns.
Main Methods:
- This commentary reviews trends in adverse event reporting for diabetes devices.
- It discusses the limitations of current data access tools, specifically the FDA website's query functionality.
- It considers potential contributing factors to the rise in adverse events, including user error.
Main Results:
- Adverse events related to diabetes devices nearly doubled between 2018 and 2019.
- The FDA's adverse event reporting system is difficult to navigate, impeding thorough examination.
- User error is identified as a common factor contributing to adverse events.
Conclusions:
- There is an urgent need to increase awareness and address the rising number of adverse events in diabetes devices.
- Improvements in data accessibility and user-centered design are crucial for effective safety monitoring.
- Further research and intervention strategies are required to reduce the incidence of these adverse events.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
763
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
763
Insulin: Dosing Regimen and Adverse Effects
531
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
531
Diabetes Mellitus: Type 2 and Gestational
4.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
Diabetes Mellitus: Overview and Type I Subtype
4.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones
503
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
503
Hypoglycemia and Glucagon
668
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
668

